AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $595.59 billion. The enterprise value is $619.58 billion.
Important Dates
The next estimated earnings date is Tuesday, April 28, 2026, before market open.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
AstraZeneca has 3.10 billion shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 3.10B |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 67.02% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 58.25 and the forward PE ratio is 37.23.
| PE Ratio | 58.25 |
| Forward PE | 37.23 |
| PS Ratio | 10.14 |
| Forward PS | 9.32 |
| PB Ratio | 12.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 50.62 |
| P/OCF Ratio | 40.86 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 32.14, with an EV/FCF ratio of 52.66.
| EV / Earnings | 60.59 |
| EV / Sales | 10.55 |
| EV / EBITDA | 32.14 |
| EV / EBIT | 43.35 |
| EV / FCF | 52.66 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 0.61.
| Current Ratio | 0.94 |
| Quick Ratio | 0.65 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | 2.52 |
| Interest Coverage | 10.47 |
Financial Efficiency
Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is 16.48%.
| Return on Equity (ROE) | 22.84% |
| Return on Assets (ROA) | 8.19% |
| Return on Invested Capital (ROIC) | 16.48% |
| Return on Capital Employed (ROCE) | 17.12% |
| Weighted Average Cost of Capital (WACC) | 5.45% |
| Revenue Per Employee | $617,655 |
| Profits Per Employee | $107,518 |
| Employee Count | 95,100 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, AstraZeneca has paid $2.17 billion in taxes.
| Income Tax | 2.17B |
| Effective Tax Rate | 17.49% |
Stock Price Statistics
The stock price has increased by +25.04% in the last 52 weeks. The beta is 0.23, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +25.04% |
| 50-Day Moving Average | 193.22 |
| 200-Day Moving Average | 166.60 |
| Relative Strength Index (RSI) | 43.03 |
| Average Volume (20 Days) | 1,938,769 |
Short Selling Information
The latest short interest is 2.38 million, so 0.08% of the outstanding shares have been sold short.
| Short Interest | 2.38M |
| Short Previous Month | 8.32M |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.15% |
| Short Ratio (days to cover) | 1.13 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $58.74 billion and earned $10.23 billion in profits. Earnings per share was $6.54.
| Revenue | 58.74B |
| Gross Profit | 47.99B |
| Operating Income | 14.29B |
| Pretax Income | 12.40B |
| Net Income | 10.23B |
| EBITDA | 19.28B |
| EBIT | 14.29B |
| Earnings Per Share (EPS) | $6.54 |
Full Income StatementBalance Sheet
The company has $5.72 billion in cash and $29.70 billion in debt, with a net cash position of -$23.98 billion or -$7.73 per share.
| Cash & Cash Equivalents | 5.72B |
| Total Debt | 29.70B |
| Net Cash | -23.98B |
| Net Cash Per Share | -$7.73 |
| Equity (Book Value) | 48.72B |
| Book Value Per Share | 31.38 |
| Working Capital | -1.89B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $14.58 billion and capital expenditures -$2.81 billion, giving a free cash flow of $11.77 billion.
| Operating Cash Flow | 14.58B |
| Capital Expenditures | -2.81B |
| Free Cash Flow | 11.77B |
| FCF Per Share | $3.79 |
Full Cash Flow StatementMargins
Gross margin is 81.71%, with operating and profit margins of 24.33% and 17.41%.
| Gross Margin | 81.71% |
| Operating Margin | 24.33% |
| Pretax Margin | 21.11% |
| Profit Margin | 17.41% |
| EBITDA Margin | 32.82% |
| EBIT Margin | 24.33% |
| FCF Margin | 20.03% |
Dividends & Yields
This stock pays an annual dividend of $3.20, which amounts to a dividend yield of 1.67%.
| Dividend Per Share | $3.20 |
| Dividend Yield | 1.67% |
| Dividend Growth (YoY) | 3.23% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 48.93% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 1.73% |
| Earnings Yield | 1.72% |
| FCF Yield | 1.98% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 6.90% |
| EPS Growth Forecast (5Y) | 3.69% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.24 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.24 |
| Piotroski F-Score | 7 |
